Leerink Swann Lowers Price Target On Vivus To $9-$11
November 04, 2009 6:37 AM
Leerink Swann lowers its price target on Vivus (Nasdaq: VVUS) from $11-$13 to $9-$11.
Leerink lowered the price target due to potential safety issues with Vivus' late-stage diet drug Qnexa.


























